JBRA Assisted Reproduction 2025;29(Suppl.2 SBRA 2025):54
Poster Presentation
29^th Annual Congress of the SBRA. São Paulo/SP - Brazil, 2025
doi: 10.5935/1518-0557.20263593

P-42. Comparative Evaluation of IVF Outcomes Using Zymot in Samples with High and Low Sperm DNA Fragmentation

Larissa Paola Coelho Pedroso¹, Diana Caroline da Silva Bastos¹, Rafaela Aguiar¹, Gabriela Melo de Souza¹, Julia Gonçalves Fella¹, Eliana Junko Morita¹, Raquel Mitie Koike¹, Enoch Quindere de Sa Barreto¹

¹ CITI Medicina Reprodutiva - São Paulo - SP - Brasil

Objective: To compare the use of microfluidic Zymot processing in patients with high and low sperm DNA fragmentation and its impact on fertilization rate, cleavage, blastocyst formation, and top-quality embryos.
Methods: Retrospective data were collected from patients who underwent in vitro fertilization (IVF) treatment using either conventional IVF or intracytoplasmic sperm injection (ICSI) between 2022 and 2025 at our Reproductive Medicine Center. All selected patients had semen processed exclusively with the Zymot microfluidic device. Only cases in which sperm DNA fragmentation testing was performed prior to the procedure were included, as well as patients who underwent cycles using either freshly retrieved oocytes or thawed oocytes. Patients were divided into two groups according to the sperm DNA fragmentation index: high fragmentation (above 15%) and low fragmentation (up to 14.99%), which was the cutoff point adopted for comparative analysis. Statistical analysis was performed using the T-test and p<0.05 was considered significant.
Results: The mean age in the control group was 39.7 years, and in the high-fragmentation group, 40.7 years (p=0.27). Regarding sperm DNA fragmentation, the control group had a mean of 8.3%, while the high-fragmentation group had a mean of 27.2% (p<0.0001). In terms of the evaluated outcomes, no statistically significant differences were observed between the groups, indicating that patients with high fragmentation, when processed with Zymot, achieved results similar to those with low fragmentation. The fertilization rate was 91.7% in the control group and 91.8% in the high-fragmentation group (p=0.527). The cleavage rate was 88.3% in the control group and 90.3% in the high-fragmentation group (p=0.299). The blastulation rate was 55.1% in the control group and 56.8% in the high-fragmentation group (p=0.565). The incidence of high-quality blastocysts was 33.5% and 38.9%, respectively (p=0.138).
Conclusion: The use of the Zymot device did not show significant differences in the evaluated parameters between the high and low fragmentation groups. This finding indicates that Zymot processing in patients with increased fragmentation yields outcomes similar to those in patients with low fragmentation. Therefore, the use of the Zymot device in high-fragmentation patients may have a positive impact on IVF treatment and is easy to apply.